CSCatherine Sebban

Catherine Sebban

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Catherine Sebban has a total of 143 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR YOUNG PATIENTS WITH FIRST-LINE FOLLICULAR LYMPHOMA: A POOLED ANALYSIS OF 4249 PATIENTS FROM THE FLASH DATABASE.

    by L. Fornecker, F. Ou, J.G. Dixon, C. Casulo, E. Hoster, W. Hiddemann, C. Sebban, F. Morschhauser, R. Marcus, H. Hochster, et al.


  • PCN60 COST-EFFECTIVENESS OF PEGFILGRASTIM VERSUS FILGRASTIM AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMA AND MYELOMA

    by L. Perrier, A. Lefranc, P. Quittet, P. Moreau, C. Siani, H. Ghesquières, F. Jardin, B. Favier, N. Ifrah, S. Lissandre, et al.

  • Association of CD4 lymphopenia with survival in patients with advanced cancer.

    by J. Peron, I. L. Ray-Coquard, S. I. Labidi-Galy, P. Heudel, G. Clapisson, P. A. Cassier, I. Philip, C. Borg, O. Tredan, T. D. Bachelot, et al.

    E21145 Background: Lymphopenia (lyp) is associated with an increased risk of toxicity and early death after cytotoxic chemotherapy (CT) in cancer patients (pts) and is also a prognostic factor for overall survival (OS) and progression free survival (PFS) in lymphoma, breast, and sarcoma pts. We report here the impact of CD4 lyp on patient survival after 10 years. Methods: 220 HIV negative pts treated in 2C dept in the Centre L.Bérard (Lyon, France) were included in this study from 04/99 to11/00. 98 (45%) had lymphoma or myeloma, 58 (26%) sarcoma, 21 (9%) breast cancer and 43 (19%) for other cancers. Two groups of diseases: 1) chemocurable diseases (NHL or germ cell tumors), 2) seldom chemocurable disease (advanced carcinomas and sarcomas). Phenotypic analysis of peripheral blood lymphocyte (ly) subsets on d1 of CT was determined using flow cytometry. Prognostic factors were analyzed univariate and multivariate analysis using Cox model. Results: With a minimum follow-up of 10 years in the entire group, age>60, PS >1, stage, tumor type, baseline ly <700/uL, CD4 count<450/uL CD8<400/uL correlated to OS in univariate analysis. Using Cox model, age, PS, stage, tumor type, use of high-risk CT, and ly subsets independently correlated to OS. In lymphoma pts, baseline ly count<700/uL, CD4 count<450/uL, CD56 count <100/uL were independent prognostic factors for OS and PFS using Cox model. In sarcoma pts, baseline ly count <700/uL, CD4 count <450/uL and CD8 count <400/uL were independent risk factors for OS and PFS in multivariate analysis. In pts with seldom chemocurable diseases (advanced carcinomas and sarcomas), all pts with total ly < 400/ uL or CD4 ly < 200/ uL died within 18 months (median: 6 mos). In lymphoma and germ cell tumor pts, all pts but one with ly< 200/ uL or CD4 lymphocytes < 100/ uL relapsed and died. Conclusions: Peripheral blood lymphocyte subsets prior to initiation of CT is a strong predictor of OS and PFS in this series. All pts with advanced breast carcinoma or sarcoma and CD4 count<200/uL had a very short term survival.


  • Rituximab plus gemcitabine and oxaliplatine (R-GemOx) in refractory/relapsed patients with diffuse large B-cell lymphoma (DLBCL) who are not candidates for high-dose therapy (HDT): A GELA study.

    by T. EL Gnaoui, H. Tilly, N. Mounier, C. Gisselbrecht, C. Sebban, O. Casasnovas, R. Delarue, T. Petrella, D. Canioni, C. Haioun

    8011 Background: We conducted a multi-center phase II trial using R-GemOx: R (375mg/m2, d1), Gem (1,000 mg/m2,d2) and Ox (100 mg/m2, d2) to confirm the efficacy and safety of an outpatient salvage regimen for patients (pts) with DLBCL non eligible for HDT(El gnaoui. Ann Oncol 2007). Methods: The primary objective was to determine the overall response rate (ORR) after 4 cycles given every 2 weeks. Patients were planned to receive 8 cycles if at least in PR after 4 cycles. Between August 2003 and January 2009, 49 pts with refractory (n=6)/relapsing (n=43, including early relapse < 12m: 16 pts) were treated in 7 institutions. Median age was 65 y (range: 41-77). Prior treatment included rituximab in 31 (63%) and HDT in 17 (35%). IPI at enrolment was > 2 in 34 pts (71%). Median delay between last treatment and R-GemOx was 14 months (m). 36 pts were in first relapse and 7 in second. Results: Sequential analyses were performed every five pts using triangular test. After 4 cycles, responses were: CR/CRu: 21 (44%), PR: 8 (17%) resulting in an ORR of 61%. At the end of treatment, 18 pts achieved CR/CRu, 4 remained in PR and 7 pts progressed. Factors significantly affecting response rate were: refractory/ early relapse 18% vs 54% (p=0.001) and prior exposure to rituximab 23% vs 65% (p=0.004). With a median follow-up of 41 m, 3y-PFS and OS were 20% (CI 10-33%) and 28% (CI 16-42%), respectively. 3y-PFS was affected by prior treatment with rituximab, 11% vs 35% (p=0.03) and refractory/early relapse 14% vs 26% (p=0.02). Grade 3-4 neutropenia and thrombocytopenia were reported for 73% and 44% of the 273 cycles delivered. A grade 3-4 infection was observed in 22% of the cycles. Conclusions: The R-GemOx regimen is a safe outpatient regimen for relapsed refractory DLBCL not candidate for HDT. This regimen could be considered as a platform for new combinations with targeted treatment in order to improve PFS, especially in refractory and early relapsed pts previously treated with rituximab. No significant financial relationships to disclose.


  • Major dispersion in etoposide systemic exposure in malignant lymphoma patients receiving BEAM high dose chemotherapy followed by ABMT: A multicentre study of the Groupe d’Etudes des Lymphomes de l’Adulte (GELA)

    by B. You, A. Michallet, G. Salles, O. Casasnovas, H. Tilly, V. Ribrag, C. Sebban, C. Falandry, B. Tranchand, G. Freyer

    8537 Background: To analyze the pharmacokinetic (PK) parameters of etoposide in patients with malignant lymphomas receiving high dose chemotherapy (BEAM: carmustine, cytarabine, etoposide and melphalan) followed by ABMT. Methods: 91 patients were included in this open multicentre prospective study at first treatment line or at relapse. BEAM comprised etoposide 100 mg/m² twice daily for 4 days. We used a limited blood sampling strategy, allowing to estimate the patients’ PK parameters with acceptable precision. Individual etoposide concentrations versus time curves as well as individual etoposide clearance (etoCL) and Area Under the Curve (etoAUC) were modelized using the NONMEM program. The distribution of total etoAUC (over the 4-day treatment) was investigated according to population quartiles. Results: The inter-individual variability in etoCL was 26.3% (95% CI=20.6–30.9%). The median etoAUC was 906.5 mg/L.h for all patients (range: 547.5–2,271.6 mg/L.h) and was not influenced by treatment line. The total etoAUC upper bounds of 1st, 2nd and 3rd quartiles were 737.5, 906.5 and 1,096.2 mg/L.h respectively. No correlations were observed between body surface area and etoCL. Conclusions: Although all patients received the same etoposide dose calculated using body surface area, we observed a major inter-individual variability in AUC. Some patients had a more than 4 fold higher systemic exposure than other patients, which may have important consequences on treatment tolerance and efficacy. Data on clinical consequences of PK variability will be presented. No significant financial relationships to disclose.

  • Open Access

    Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge

    by Catherine Sebban, Sophie Dussart, Christine Fuhrmann, Hervé Ghesquieres, Isabelle Rodrigues, Lionel Geoffrois, Yves Devaux, Laurence Lancry, Giselle Chvetzoff, Thomas Bachelot, et al.

    Patients with low-risk neutropenic fever as defined by the Multinational Association of Supportive Care in Cancer (MASCC) score might benefit from ambulatory treatment. Optimal management remains to be clearly defined, and new oral antibiotics need to be evaluated in this setting. Cancer patients with febrile neutropenia and a favorable MASCC score were randomized between oral moxifloxacin and intravenous ceftriaxone. All were fit for early hospital discharge. The global success rate was related to the efficacy of monotherapy, as well as to the success of ambulatory monitoring. The trial was closed prematurely because of low accrual. Ninety-six patients were included (47 in the ceftriaxone arm and 49 in the moxifloxacin arm). A total of 65% were women, 30.2% had lymphoma, 34.4% had metastatic, and 35.4% had non-metastatic solid tumors. The success rates of home antibiotics were 73.9% and 79.2% for ceftriaxone and moxifloxacin, respectively. Seven patients were not discharged, and 14 required re-hospitalization. There were 17% of microbiologically documented infections that were, in most cases, susceptible to oral monotherapy. These results suggest that MASCC is a valid and useful tool to select patients for ambulatory treatments and that oral moxifloxacin monotherapy is safe and effective for the outpatient treatment of cancer patients with low-risk neutropenic fever.


  • Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

    by Catherine Sebban, Nicolas Mounier, Nicole Brousse, Coralie Belanger, Pauline Brice, Corinne Haioun, Herve Tilly, Pierre Feugier, Redah Bouabdallah, Chantal Doyen, et al.

    The purpose of this study is to compare our standard chemotherapy regimen (CHVP [cyclophosphamide, doxorubicin, teniposide, and prednisone]) plus interferon with 4 courses of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by high-dose therapy with autologous stem cell transplantation (ASCT) in treatment-naive patients with advanced follicular lymphoma. Four hundred one patients were included from July 1994 to March 2001: 209 received 12 cycles of CHVP plus interferon α for 18 months (CHVP-I arm) and 192 received 4 cycles of CHOP followed by high-dose therapy (HDT) with total body irradiation and ASCT (CHOP-HDT arm). Overall response rates were similar in both groups (79% and 78% after induction chemotherapy, respectively). One hundred thirty-one of the 150 patients eligible for HDT underwent transplantation (87%). Intent-to-treat analysis after a median follow-up of 7.5 years showed that there was no difference between the 2 arms for overall survival (P = .53) or event-free survival (P = .11). Patients with a complete response at the end of the induction therapy had a statistically longer event-free survival and overall survival (P = .02 and < .001, respectively). After long-term follow-up, our study showed that there was no statistically significant benefit in favor of first-line high-dose therapy in patients with follicular lymphoma. High-dose therapy should be reserved for relapsing patients.


  • Home health care and short febrile neutropenia after chemotherapy: analyse of a two years experimental study made in a cancer centre

    by C. Sebban, C. Fuhrmann, D. Pérol, Y. Devaux, H. Ghesquière, S. Galand-Desmé, N. Lévêque, L. Claude, P. Biron

    L’étude a pour but de tester la faisabilité d’une prise en charge précoce à domicile des aplasies fébriles sans facteurs de mauvais pronostic. Sur 517 épisodes de neutropénies fébriles enregistrés entre 07/99 et 06/01, seuls 52 cas ont bénéficié de cette prise en charge avec Céfépime 2g 2 fois par jour. Dans les autres cas, il existait des facteurs de mauvais pronostic ou des échecs organisationnels. Sur les 52 cas, 50 cas ont été des succès avec retour à domicile rapide, antibiothérapie efficace et absence de réhospitalisation. Dans les 2 autres cas, le départ a du être différé pour complications. Cette stratégie est donc tout à fait optimale sur une population correctement sélectionnée. Les nouveaux scores pronostics de la neutropénie fébrile et le développement croissant des soins à domicile devraient permettre d’élargir la population cible pour cette prise en charge ambulatoire. The aim of this study is to determine the feasibility of early home care for febrile aplasia when there are no poor diagnostic factors. Of 517 episodes of febrile neutropenia recorded between July 1999 and June 2001, only 52 have benefited from early home care with Cefepime 2 g, twice a day. In the other cases, there were poor prognostic factors or organizational failures. Of the 52 cases, 50 had favorable outcomes after early hospital discharge and effective antibiotic therapy, with no need for readmission to hospital. For the remaining two cases, discharge was postponed because of complications. This is, therefore, clearly the optimal treatment strategy for a carefully selected patient population. New prognostic scoring for febrile neutropenia and the ongoing development of home care services should make it possible to expand the target population for this type of outpatient care.


    • 1 September 2002
      • Vol. 50  (4) , 393-403

    [Necessary harmonization of health cost assessment. Autologous peripheral blood progenitor cell transplantation in France].

    by Lionel Perrier, C Sebban, I Philip, B Standaert, M Morelle, J F Latour, P Biron, T Philip

    The purpose of this study was to determine to what extent methods used to assess health cost affect the total cost of a therapeutic procedure. We assessed total cost of 160 consecutive therapeutic intensification procedures using autologous blood progenitor cell transplantation, 95 for lymphoma and 65 for breast tumor. The average total cost of the therapeutic intensification for patients with lymphoma was 227156 francs (34630 euros), including 60720 francs (9257 euros) for mobilization, 14947 francs (22402 euros) for the treatment period and 19489 francs (2971 euros) for secondary hospitalization. The average total cost for patients with a breast tumor was 199626 francs (30433 euros), including 39269 francs (5987 euros) for mobilization, 14912 francs (22737 euros) for the treatment period, and 11215 francs (1709 euros) for secondary hospitalization. We compared our findings with those from six earlier French studies. Differences in the methodologies used focuses attention on the need for incentives for better harmonization of health cost assessment.

    • 15 June 2000
      • Vol. 95  (12) , 3687-92

    Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA).

    by N Mounier, C Haioun, B F Cole, C Gisselbrecht, C Sebban, P Morel, G Marit, R Bouabdallah, C Ravoet, G Salles, et al.

    Evaluating high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) in term of both duration and quality of life (QOL) presents major interests for patients with non-Hodgkin lymphoma. The quality-adjusted time without symptom and toxicity (Q-TWiST) methodology was applied to the LNH87-2 trial comparing HDT with ASCT versus sequential chemotherapy in 541 patients in first complete remission (CR). Overall survival (OS) and disease-free survival (DFS) curves were used to estimate duration of 4 health states: acute short-term toxicity (Tox1), secondary toxicity (Tox2), time without symptom and toxicity (TWiST), and relapse (Rel). Areas under survival curves (AUC) were retrospectively weighted according to QOL coefficients. HDT increased, but not significantly, TWiST (+2. 4 months in AUC, P =.17) and decreased Rel (-3 months, P <.01). Survival estimates did not differ between the 2 treatments (AUC 47.7 months for OS, 39.7 months for DFS). High-risk patients treated by HDT versus chemotherapy had a significant benefit in DFS (AUC 28.8 versus 24.9 months, P <.01) but not in OS (AUC 37.3 versus 36 months, P =.27). Sensitivity analysis, performed by varying QOL coefficients, demonstrated significant quality-adjusted survival gain in high-risk patients treated by HDT. In low-risk patients, a diagram provided an aid to clinical decision-making. This analysis supports the use of HDT in these patients with adverse prognostic factors in the first CR, even after adjusting for QOL using the Q-TWiST method. (Blood. 2000;95:3687-3692)